GlaxoSmithKline sales get boost from Covid and shingles therapy | Business

Supplies of a Covid antibody treatment and a recovery in sales of a blockbuster shingles vaccine helped to lift quarterly sales at GlaxoSmithKline by a third, boosting its shares before the break-up of the drugs group this summer.

Sales rebounded by 32 per cent to almost £9.8 billion and adjusted operating profit by 39 per cent to £2.6 billion, ahead of City forecasts and helped by a favorable pandemic comparison with last year when the disrupted trading.

Dame Emma Walmsley, the chief executive, said it was a strong first quarter in a “landmark year” for GSK.

Walmsley, 52, said GSK remained on course to spin off Haleon, the new name given to its consumer healthcare business, on the London Stock Exchange in July, which would

Leave a Comment

Your email address will not be published.